The first end position was the security and tolerability of sifalimumab. Treatment-emergent adverse events (AEs) and critical AEs (SAEs) and their severity, result, and any partnership for the review medication were being recorded by the investigator through the entire examine. AEs had been regarded very likely to be related to https://benjaminf443rdo6.wikijournalist.com/user